The U.S. beef cattle health market size was estimated at USD 1.12 billion in 2024 and is projected to reach USD 2.35 billion by 2033, growing at a CAGR of 8.80% from 2025 to 2033. The market is experiencing growth driven by the rising prevalence of infectious and parasitic diseases, shrinking cattle herds prompting greater focus on animal health and productivity, and increasing investments in preventive veterinary care. Additionally, high cattle values and biosecurity concerns are accelerating the adoption of vaccines, diagnostics, and health monitoring technologies across beef operations.
Rising disease prevalence among cattle, both endemic and emerging, has become a major growth driver for the U.S. beef cattle health industry, pushing increased demand for diagnostics, vaccines, therapeutics, and preventive strategies. For example, as per the USDA report, Bovine Respiratory Disease (BRD) remains one of feedlot cattle’s costliest health issues. Several studies show that reductions in mortality and morbidity from BRD improve animal welfare, affect beef supply, lower costs, and influence downstream markets for cattle, feed, and beef prices.
Another example is the re-emergence of the New World Screwworm, which threatens supply by prompting import bans (e.g., from Mexico), increasing treatment and biosecurity costs, and pushing beef prices upward. In response, cattle producers are investing more heavily in animal health infrastructure: enhanced surveillance, rapid diagnostics, new vaccines or antiparasitic drugs, and improved herd management practices. This investment is enlarging the cattle healthcare market. According to the USDA, in 2024, the U.S. accounted for almost 87% of the North American cattle healthcare market. Preventive healthcare, diagnostics, precision livestock farming, and therapeutics are all growing segments in the U.S. market. These trends also signal that producers and policymakers recognize disease prevention as economically essential to safeguard animals and ensure market stability, export access, and beef affordability.
Additionally, the rising number of FDA-approved drugs for beef cattle is driving the U.S. beef cattle health market, as it expands the range of available preventive and therapeutic options for producers. Recent approvals, such as Dectomax-CA1 for New World screwworm prevention and Pradalex for bovine respiratory disease, provide ranchers with practical tools to protect herd health, reduce mortality, and improve productivity. These approvals also encourage the adoption of biologics, pharmaceuticals, and medicated feed additives, enabling producers to manage disease more efficiently and mitigate economic losses, fueling overall market growth.
This product will be delivered within 2 business days.
Rising disease prevalence among cattle, both endemic and emerging, has become a major growth driver for the U.S. beef cattle health industry, pushing increased demand for diagnostics, vaccines, therapeutics, and preventive strategies. For example, as per the USDA report, Bovine Respiratory Disease (BRD) remains one of feedlot cattle’s costliest health issues. Several studies show that reductions in mortality and morbidity from BRD improve animal welfare, affect beef supply, lower costs, and influence downstream markets for cattle, feed, and beef prices.
Another example is the re-emergence of the New World Screwworm, which threatens supply by prompting import bans (e.g., from Mexico), increasing treatment and biosecurity costs, and pushing beef prices upward. In response, cattle producers are investing more heavily in animal health infrastructure: enhanced surveillance, rapid diagnostics, new vaccines or antiparasitic drugs, and improved herd management practices. This investment is enlarging the cattle healthcare market. According to the USDA, in 2024, the U.S. accounted for almost 87% of the North American cattle healthcare market. Preventive healthcare, diagnostics, precision livestock farming, and therapeutics are all growing segments in the U.S. market. These trends also signal that producers and policymakers recognize disease prevention as economically essential to safeguard animals and ensure market stability, export access, and beef affordability.
Additionally, the rising number of FDA-approved drugs for beef cattle is driving the U.S. beef cattle health market, as it expands the range of available preventive and therapeutic options for producers. Recent approvals, such as Dectomax-CA1 for New World screwworm prevention and Pradalex for bovine respiratory disease, provide ranchers with practical tools to protect herd health, reduce mortality, and improve productivity. These approvals also encourage the adoption of biologics, pharmaceuticals, and medicated feed additives, enabling producers to manage disease more efficiently and mitigate economic losses, fueling overall market growth.
U.S. Beef Cattle Health Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. beef cattle health market report based on product and distribution channel:Product Outlook (Revenue, USD Million, 2021-2033)
- Biologics
- Pharmaceuticals
- Medicated Feed Additives
Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Retail
- E-commerce
- Hospital/Clinic Pharmacy
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Report Deliverables
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variable Trends & Scope
Chapter 4. U.S. Beef Cattle Health Market: Product Estimates & Trend Analysis
Chapter 5. U.S. Beef Cattle Health Market: by Distribution Channel Estimates & Trend Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this U.S. Beef Cattle Health market report include:- Boehringer Ingelheim International GmbH
- Zoetis Inc.
- Merck & Co., Inc
- Vetoquinol S.A
- Elanco Animal Health Incorporated
- Virbac
- Phibro Animal Health Corporation
- Norbrook
- Dechra Pharmaceuticals Plc
- Bimeda, Inc
- Cargill, Incorporated
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | October 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 1.12 Billion |
| Forecasted Market Value ( USD | $ 2.35 Billion |
| Compound Annual Growth Rate | 8.8% |
| Regions Covered | United States |
| No. of Companies Mentioned | 12 |
